Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2013; 34(03): 206-207
DOI: 10.4103/0971-5851.123744
ORIGINAL ARTICLE

Report of chronic myeloid leukemia in chronic phase from Cancer Institute (Women India Association), Chennai, 2002-2009

Prasanth Ganesan
Department of Medical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
,
R Rejiv
Department of Medical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
,
N Manjunath
Department of Medical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
,
C Sanju
Department of Medical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
,
T G Sagar
Department of Medical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

Cancer Institute Chennai is the first Institute of Oncological sciences to be established in the country. In ICON meeting, they presented the data of 516 patients, of which 91% patients achieved complete hematological response. The overall survival was 88% and event free survival was 65% at 5 years.

Keywords

Chennai - chronic myeloid leukemia - Women India Association


Publication History

Article published online:
19 July 2021

© 2013. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Marin D, Marktel S, Bua M, Armstrong L, Goldman JM, Apperley JF, et al. The use of imatinib (STI571) in chronic myelod leukemia: Some practical considerations. Haematologica 2002;87:979-88.
  • 2 Deininger MW, O′Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003;21:1637-47.
  • 3 Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-20.